

Pandemic influenza preparedness Framework

for the sharing of influenza viruses
and access to vaccines and
other benefits

SECOND EDITION



**World Health
Organization**

Pandemic influenza preparedness Framework

for the sharing of influenza viruses
and access to vaccines and
other benefits

SECOND EDITION



**World Health
Organization**

Pandemic Influenza Preparedness (PIP) Framework for the sharing of influenza viruses and access to vaccines and other benefits, second edition

ISBN 978-92-4-002485-4 (electronic version)

ISBN 978-92-4-002486-1 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Pandemic Influenza Preparedness (PIP) Framework for the sharing of influenza viruses and access to vaccines and other benefits, second edition. Geneva: World Health Organization; 2021. Licence: **CC BY-NC-SA 3.0 IGO**.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Foreword	v
WHA 64.5 Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccine sand other benefits	1
WHA 72(12) Pandemic Influenza Preparedness: sharing of influenza viruses and access to vaccines and other benefits	2
1. Principles	3
2. Objective	6
3. Scope	7
4. Definitions and use of terms	8
4.1 Pandemic influenza preparedness biological materials or PIP biological materials	8
4.2 Other technical terms	8
4.3 Institutions, organizations and entities	10
4.4 Other terms	11
5. Pandemic influenza preparedness system for sharing of H5N1 and other influenza viruses with human pandemic potential	12
5.1 General	12
5.2 Genetic sequence data	12
5.3 Traceability and reporting mechanisms	13
5.4 Standard Material Transfer Agreements	14
6. Pandemic influenza preparedness benefit sharing system	15
6.0 General	15
6.1 WHO Coordination of pandemic influenza preparedness and response	15
6.2 Pandemic risk assessment and risk response	16
6.3 Provision of PIP candidate vaccine viruses	16
6.4 Provision of diagnostic reagents and test kits	17

6.5	Provision of reference reagents for potency determination of vaccines	17
6.6	Laboratory and influenza surveillance capacity building	17
6.7	Regulatory capacity building	18
6.8	Antivirals stockpiles	18
6.9	Pandemic influenza preparedness vaccine stockpile	18
6.10	Access to vaccines in the inter-pandemic period for developing countries	19
6.11	Access to pandemic influenza vaccines	20
6.12	Tiered pricing	20
6.13	Technology transfer	20
6.14	Sustainable and innovative financing mechanisms	21
7.	Governance and review	23
7.1	General	23
7.2	Advisory Group	23
7.3	Governance and review of terms of reference for WHO global influenza surveillance and response system (GISRS) laboratories	24
7.4	Monitoring and review of the Pandemic Influenza Preparedness Framework	25
Annexes		27
Annex 1	Standard Material Transfer Agreement 1	29
Annex 2	Standard Material Transfer Agreement 2	33
Annex 3	Advisory Group terms of reference	37
Annex 4	Guiding Principles for the development of terms of reference for current and potential future WHO global influenza surveillance and response system (GISRS) laboratories for H5N1 and other human pandemic influenza viruses	40
Annex 5	Terms of reference related to work with pandemic influenza preparedness biological materials	42

Foreword

This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, as decided by the Seventy-second World Health Assembly.¹ The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA2. The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).

¹ See decision WHA72(12), available at: https://apps.who.int/gb/ebwha/pdf_files/WHA72-REC1/A72_2019_REC1-en.pdf#page=74

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23387

